Medanta (Global Health) Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook

Medanta (Global Health) (GLOBALHEALTH) Q4 results for FY26 are expected in May 2026. With Q3 FY26 revenue of Rs 885 Cr and PAT of Rs 118 Cr as the base, the street is watching closely for margin trajectory and management guidance on FY27 demand.

Get Free SEBI-Registered Research on Medanta (Global Health) — Click Here

Medanta (Global Health) Q4 FY26 Earnings Preview — What to Expect

India’s healthcare diagnostics sector maintains solid growth momentum in Q4 FY26, backed by rising health awareness, insurance penetration expansion and a robust preventive testing trend driving test volumes across the country.

Medanta (Global Health) Q4 Results 2026 — Date and Key Estimates

Parameter	Q3 FY26 Actual	Q4 FY26 Estimate	YoY Growth
Revenue (Rs Cr)	885	972	+10%
PAT (Rs Cr)	118	138	+17%
EBITDA Margin	—	14.2%	Improvement expected
Results Date	—	May 2026	—
Dividend History	Rs 1.00 per share
Dividend Expectation	Rs 1.50 final dividend expected

Estimates based on analyst consensus as of April 2026. Actual results may vary. Verify before investing.

Track Medanta (Global Health) live price, FII/DII activity and fundamentals on Univest Screener

5 Reasons Medanta (Global Health) Q4 Results Could Beat Estimates

Preventive Healthcare Demand

Growing health consciousness and rising insurance coverage are driving strong demand for health checkup packages and chronic disease monitoring tests, both of which carry higher margins.

Network Expansion into Tier-2 and Tier-3 Cities

Diagnostic chains are capturing untapped demand in semi-urban India through hub-and-spoke lab models and home collection services, expanding addressable market significantly.

Specialised Testing Growth

High-value testing in genomics, immunology, molecular diagnostics and oncology is growing rapidly, improving revenue per patient and blended margin profiles.

Institutional and B2B Business

Tie-ups with hospitals, corporates and insurance companies for dedicated diagnostic services create stable, recurring B2B revenue with lower customer acquisition costs.

Digital Health Platform Integration

Digital booking, home collection and online reporting platforms are improving patient experience, loyalty and repeat testing rates, reducing churn and acquisition costs.

5 Key Risks to Watch in Medanta (Global Health) Q4 Results

Price War from Competition

Aggressive discounting by unorganised labs and newer entrant chains pressures realisations and tests-per-patient metrics across markets.

Regulatory Quality Requirements

NABL accreditation maintenance, CGHS panel compliance and quality audits add ongoing operational costs that weigh on margins.

Capital Intensity of Network Expansion

Setting up new collection centres and processing labs requires significant capital; ROI typically takes 2-3 years to fully materialise.

Equipment Upgrade Capex

Rapid diagnostic technology evolution requires continuous equipment replacement investment, adding recurring capex pressure.

Insurance Reimbursement Pressure

Health insurers negotiating lower reimbursement rates for diagnostic tests can reduce revenue per test over time.

Analyst Ratings and Target Price for Medanta (Global Health)

Brokerage	Rating	Key Thesis
Emkay Global	Buy	Network expansion and volume recovery on track
JM Financial	Neutral	Competition intensity remains a concern
ICICI Direct	Buy	Preventive health demand and B2B growth drivers

Analyst ratings are for informational purposes only and subject to change. Not investment advice.

Medanta (Global Health) share price (GLOBALHEALTH) is trading near Rs 865 with a market capitalisation of approximately Rs 21,500 Cr. Track the stock on Univest Screener for live price and fundamental data.

Q4 Results 2026 Calendar — Key Dates to Track

Company	Expected Results Date
Medanta (Global Health)	May 2026
TCS	April 2026
Infosys	April 2026

Stay updated on all Q4 FY26 earnings at Univest Blogs. For TCS results see TCS Q4 Results 2026 and for Infosys see Infosys Q4 Results 2026.

How to Invest in Medanta (Global Health) Based on Q4 Results

Before investing in Medanta (Global Health) based on Q4 results, consider the following approach: review the actual revenue and PAT versus analyst estimates, listen to the management earnings call for FY27 guidance, assess whether the EBITDA margin trajectory is improving or deteriorating, and check FII/DII activity patterns post-results. A beat on estimates with positive guidance is typically a bullish signal; a miss with downgraded guidance may indicate further correction risk.

Subscribe to Univest Pro for SEBI-registered entry, target and stop-loss levels on Medanta (Global Health) — Click Here

Frequently Asked Questions — Medanta (Global Health) Q4 Results 2026

Q: When will Medanta (Global Health) announce Q4 FY26 results?

Medanta (Global Health) (GLOBALHEALTH) is expected to announce Q4 FY26 results in May 2026. The exact board meeting date will be communicated via BSE/NSE exchange filing. Track the date on Univest Screener.

Q: What is the revenue estimate for Medanta (Global Health) Q4 FY26?

Analyst consensus estimates Medanta (Global Health) Q4 FY26 revenue at approximately Rs 972 Cr, representing approximately 10% year-on-year growth. The actual number will depend on sector demand trends and execution in the quarter.

Q: What PAT is expected for Medanta (Global Health) in Q4 FY26?

Estimated PAT for Medanta (Global Health) Q4 FY26 is approximately Rs 138 Cr, up approximately 17% year-on-year. Margin expansion from operating leverage and input cost moderation are the primary drivers of profit growth expectations.

Q: Will Medanta (Global Health) declare a dividend in Q4 FY26?

Historical dividend pattern for Medanta (Global Health): Rs 1.00 per share. For Q4 FY26, Rs 1.50 final dividend expected. Dividend declarations are subject to board approval at the time of results.

Q: What is the current share price and market cap of Medanta (Global Health)?

Medanta (Global Health) (GLOBALHEALTH) is currently trading at approximately Rs 865 with a market capitalisation of Rs 21,500 Cr. Track live price, volume and FII/DII data on Univest Screener.

Q: What are the key risks for Medanta (Global Health) in Q4 FY26?

Key risks include: Price War from Competition, Regulatory Quality Requirements, Capital Intensity of Network Expansion. Investors should monitor management commentary on these risks in the Q4 earnings call.

Q: Is Medanta (Global Health) a buy before Q4 results?

This article does not constitute investment advice. Whether to buy Medanta (Global Health) before Q4 results depends on your risk appetite, existing portfolio exposure and entry price relative to fair value. Consult a SEBI-registered financial advisor before making any investment decision.

Q: How can I track Medanta (Global Health) Q4 results live?

Track Medanta (Global Health) Q4 FY26 results live on the Univest Screener, which provides real-time price updates, financial data and analyst research. Download the Univest iOS App or Android App for mobile alerts.

Disclaimer: Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Consult a SEBI-registered financial advisor before making any investment decisions. SEBI Registration: INH000012449.

Recent Article

Why Is Ahluwalia Contracts Share Price Falling Key Reasons 2026

Why Is Ahluwalia Contracts Share Price Falling Key Reasons 2026

Why Is Nuvoco Vistas Corporation Share Price Falling Key Reasons 2026

Why Is Capacite Infraprojects Share Price Falling Key Reasons 2026

Why Is PSP Projects Share Price Falling Key Reasons 2026